New Products

SPOKANE, Wash. — Zak Designs on Tuesday announced the latest product license for its line of dinnerware for kids.

Zak is releasing two lines of mealtime products featuring characters from two Disney Junior animated shows: "Jake and the Never Land Pirates" and "Doc McStuffins."

PRINCETON, N.J. — Generic drug maker Sandoz has launched a generic version of a drug used to treat high blood pressure and angina.

The company, a subsidiary of Swiss drug maker Novartis, announced the launch of diltiazem hydrochloride extended-release capsules, a generic version of Forest Labs' Tiazac. Sandoz is launching the drug in the 120-mg, 180-mg, 240-mg, 300-mg, 360-mg and 420-mg strengths.

Various versions of the drug had sales of about $174 million in 2012, according to IMS Health.

NEW YORK — Following the 2012 launch of its Micro-Pedi home pedicure tool, Emjoi is now adding two new attachments — the Micro-Pedi Precision Kit and the Micro-Pedi Manicure Kit — that will turn any Micro-Pedi into a complete foot and hand care system.

Both the Micro-Pedi Precision Kit and the Micro-Pedi Manicure Kit’s five different attachments are inserted to one side of the Micro-Pedi tool’s head into a special silver-tone roller, which spins them 30 times per second and, in the case of the Precision Cone model, 360 degrees.

DORNSTETTEN, Germany — The family-owned Schupp GmbH and Co. KG company has just developed and launched a new type of kinesiology tape, the company announced today.

CHICAGO — Jill Stack Naturals has announced the launch of Gold-N-SPF, an herbal vegan sunscreen made with sensitive skin in mind. 

MINONG, Wis. — Jack Link's announced earlier this month the introduction of a new line of products with packaging and graphics targeted toward the millennial generation.

NEW YORK — Nail care brand Orly has unveiled its summer 2013 nail lacquer collection dubbed Mash Up.

The six-shade collection includes:

• Choreographed Chaos: Bubblegum pink chrome;


• Harmonius Mess: Lavender crème;


• Mayhem Mentality: Vibrant orange crème;

• 
Sparkling Garbage: Saturated green with holographic glitter;


LONDON — A Food and Drug Administration panel has recommended that the agency approve an experimental drug for chronic obstructive pulmonary disease made by GlaxoSmithKline and Theravance, the two companies said.

The FDA Pulmonary-Allergy Drugs Advisory Committee voted 9-4 to recommend Breo Ellipta as a long-term maintenance treatment for airflow obstruction in patients with COPD and for reduction of COPD exacerbations in patients with a history of them. The drug is a once-daily inhaler that combines fluticasone furoate and vilanterol.